Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial
- Resource Type
- Source
- The Lancet Respiratory Medicine.
- Subject
Pulmonary and Respiratory Medicine - Language
- ISSN
- 2213-2600